Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease

Walkiewicz, Dorota; Werlin, Steven L.; Fish, Daryl; Scanlon, Matthew C.; Hanaway, Patrick; Kugathasan, Subra

doi:10.1002/ibd.20376

Cited by 120 publications

(72 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Others have obtained similar fecal calprotectin concentration in both diseases [12,15,26,28] or directed attention to the strong correlation between the activity disease in patients with CD [13,29]. Kosiara and Komraus [14,27] have observed lower average concentration of fecal calprotectin in patients with CD; however, other authors have noted in patients in remission higher content of fecal calprotectin in patients with CD [12,20,26].…”

Section: Discussionmentioning

confidence: 99%

“…Some of the authors postulate that the correlation between fecal calprotectin concentration and the activity of the disease is stronger in the case of UC than in CD, which is linked with a rare involvement of the large intestine and with a lack of a complete mucosal healing even in remission phase [7,23,25]. Others have obtained similar fecal calprotectin concentration in both diseases [12,15,26,28] or directed attention to the strong correlation between the activity disease in patients with CD [13,29]. Kosiara and Komraus [14,27] have observed lower average concentration of fecal calprotectin in patients with CD; however, other authors have noted in patients in remission higher content of fecal calprotectin in patients with CD [12,20,26].…”

Section: Discussionmentioning

confidence: 99%

“…At the same time, since calprotecitn is a protein which is resistant to intestinal proteolysis it can be stored and transported at ambient temperature even for up to 5 to 7 days without losing activity. Its determination in the sample is simple and does not generate additional costs [2,3,[6][7][9][10][11][12][13][14][15][16].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Krzesiek¹

2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Children constitute 20% of patients with inflammatory bowel diseases (IBD). Still there is a search for a perfect marker for this group of patients which would help in the diagnosis of the disease, in determinating its activity and in monitoring the treatment. Objectives. Evaluate the usefulness of the application of calprotectin measurement in stool samples from children with IBD, as a marker of the severity of inflammation. Material and Methods. We analysed 156 patients: 58 with ulcerative colitis (UC), 67 with Crohn's disease (CD), and 31 from the control group. In all patients the concentration of calprotectin in the sample of feces, markers of inflammation and hemoglobin were measured. Results. Concentration of calprotectin in feces of patients with IBD was above the normal range in all patients with moderate and severe disease and in the majority with mild disease or in remission, but it was normal in all patients from the control group. Conclusions. Elevated concentration of fecal calprotectin (FC) was observed in the majority of patients with IBD, but in none from the control group. The number of patients with elevated FC concentration increased together with the disease activity. FC concentration was higher in patients with severe and moderate disease activity. FC concentration in patients with IBD was associated with the increase of inflammatory markers and decreased haemoglobin. Percentage of laboratory abnormalities in children with Crohn's disease and perianal changes was higher. FC concentration can be a noninvasive marker of disease activity in IBD (Adv Clin Exp Med 2015, 24, 5, 815-822).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Krzesiek¹

2015

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…A FC value above 400 µg/g in asymptomatic CD patients, predicted relapse within 9 months of collection in 89% of patients (95% confidence interval [CI] 51.8-99.7, p = 0.03) compared to no clinical relapse within 9 months when FC values were below 400 µg/g. 47 Similarly, van Rheenen 48 reported that teenagers with a FC above 500 µg/g had a 53% (10/19) risk of progressing to symptomatic relapse within 3 months, whereas a value below 500 µg/g only had a 12% (5/43) risk of symptomatic relapse. A retrospective analysis of 73 children with IBD found that a FC concentration of 275 µg/g had sensitivity and negative predictive value (NPV) of 97% and specificity and a positive predictive value (PPV) of 97%, with a likelihood ratio of 6.4 for predicting IBD relapse.…”

Section: A Marker Of Inflammatory Bowel Diseasementioning

confidence: 98%

“…A few investigators took a step forward to evaluate FC as a predictive marker of IBD relapse in children. Walkiewicz et al 47 examined 32 children with IBD, 11 of those with CD. A FC value above 400 µg/g in asymptomatic CD patients, predicted relapse within 9 months of collection in 89% of patients (95% confidence interval [CI] 51.8-99.7, p = 0.03) compared to no clinical relapse within 9 months when FC values were below 400 µg/g.…”

Section: A Marker Of Inflammatory Bowel Diseasementioning

confidence: 99%

Calprotectin: Clinical Applications in Pediatrics

Herrera

Christensen

Helms

2016

The Journal of Pediatric Pharmacology and Therapeutics

View full text Add to dashboard Cite

As seen over the past 20 years, calprotectin has evolved as a novel, non-invasive biomarker of gastrointestinal (GI) inflammation. We present this review of calprotectin in pediatrics. This article will focus on studies using calprotectin concentrations from different body fluids to monitor inflammation in different disease states and conditions. The ultimate goal of our group is to lay down a foundation as we consider using calprotectin prospectively as a marker of intestinal inflammation that could lead to further testing and possibly a marker of preparedness for feeding. We surveyed all published studies in English of calprotectin in neonates, infants, children, and adolescents through February 2014. We will discuss calprotectin's basic properties and analysis such as characteristics, identification, presence in body fluids, and maturational development. In addition, calprotectin's use in inflammatory diseases exploring both GI and non-GI conditions will be evaluated and compared with other serum markers presently available. Finally, a summary of our findings and discussion of future work that could be undertaken in order to render calprotectin as a more useful monitoring tool to the medical research community will complete the review.

show abstract

Biomarkers in IBD: Myth or Marvel?

Gearry

Day

2011

Clinical Dilemmas in Inflammatory Bowel Disease

View full text Add to dashboard Cite

Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease

Abstract: FC levels differentiate active IBD from controls. Among children with CD and in remission, FC levels may be useful in predicting impending clinical relapse.

Cited by 120 publications

References 38 publications

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Calprotectin: Clinical Applications in Pediatrics

Biomarkers in IBD: Myth or Marvel?

Contact Info

Product

Resources

About